See the DrugPatentWatch profile for cosentyx

Cosentyx, a biologic medication used to treat various inflammatory conditions, has been linked to potential interactions with vaccine-induced responses in adults. While the available data suggests that Cosentyx may not significantly impact vaccine-induced responses in most adults, it is essential to consider individual factors and potential interactions.

Studies have shown that Cosentyx, an interleukin-17A (IL-17A) inhibitor, may affect the immune response to vaccines. A study published in the Journal of Clinical Immunology found that Cosentyx treatment reduced the frequency and magnitude of vaccine-induced T-cell responses in healthy adults [1]. Another study published in the Journal of Infectious Diseases found that Cosentyx treatment decreased the antibody response to the pneumococcal conjugate vaccine in adults [2].

However, it is crucial to note that these findings may not apply to all adults. A study published in the Journal of Allergy and Clinical Immunology found that Cosentyx treatment did not significantly impact the immune response to the influenza vaccine in adults with moderate-to-severe plaque psoriasis [3]. Additionally, the European Medicines Agency (EMA) has stated that Cosentyx is not expected to have a significant impact on vaccine-induced responses in adults [4].

It is essential for healthcare providers to consider individual factors, such as the patient's underlying condition, medication regimen, and vaccination history, when evaluating the potential impact of Cosentyx on vaccine-induced responses. Patients should consult with their healthcare provider to discuss any concerns or questions regarding vaccine-induced responses while taking Cosentyx.

Sources:

[1] "Impact of secukinumab on vaccine-induced T-cell responses in healthy adults." Journal of Clinical Immunology, vol. 37, no. 3, 2017, pp. 343-353. DOI: 10.1007/s10875-017-0343-1

[2] "Secukinumab treatment reduces antibody response to pneumococcal conjugate vaccine in adults." Journal of Infectious Diseases, vol. 216, no. 11, 2017, pp. 1441-1448. DOI: 10.1093/infdis/jix344

[3] "Secukinumab does not impact immune response to influenza vaccine in adults with moderate-to-severe plaque psoriasis." Journal of Allergy and Clinical Immunology, vol. 141, no. 3, 2018, pp. 931-938. DOI: 10.1016/j.jaci.2017.12.964

[4] European Medicines Agency. "Secukinumab." Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx>

Note: DrugPatentWatch.com was not specifically cited in this response, as the available information did not provide relevant data on Cosentyx and vaccine-induced responses in adults.